ESR1 and breast carcinoma: In an attempt to investigate the possible pathways of resistance to CDK4/6 inhibitors, a phase III open-label multicenter trial (PADA-1 trial) was conducted in France investigating the possible implication of the ESR1 mutation on acquiring resistance to treatment in HR+/HER2− breast cancer (first randomized trial to do so).